(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/126884 A1

(51) International Patent Classification:
A61K 9/08 (2006.01)

(21) International Application Number:
PCT/US2020/065166

(22) International Filing Date:
15 December 2020 (15.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/948,735	16 December 2019 (16.12.2019)	US
62/967,920	30 January 2020 (30.01.2020)	US
62/988,720	12 March 2020 (12.03.2020)	US
63/033,773	02 June 2020 (02.06.2020)	US
63/064,671	12 August 2020 (12.08.2020)	US

(71) Applicant *(for all designated States except US)*: **TENAX THERAPEUTICS, INC.** [US/US]; 1 Copley Parkway, Suite 490, Morrisville, NC 27560 (US).

(72) Inventors; and

(71) Applicants *(for US only)*: **RANDALL, Douglas** [US/US]; C/o Tenax Therapeutics, Inc., 1 Copley Parkway, Suite 490, Morrisville, NC 27560 (US). **HAY, Douglas** [US/US]; 497 Geigel Hill Road, Ottsville, PA 18942 (US).

(74) Agent: **GERSHIK, Gary, J.**; Cooper & Dunham LLP, 90 Park Avenue, 21st Floor, New York, NY 10016 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)

(57) Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.




Figure 1A

WO 2021/126884 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*